Danish pharmaceutical logos Novo Nordsek, scent diabetes maker and weight loss treatments, sees OzemPIC and Wegovy outside the Theeri building where the company provides the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Gety pictures
On Friday, Denmark reduced its annual growth expectations to 1.4 % of 3 %, and this is largely due to the weakest pharmaceutical giant expectations Novo Nordsk.
Denmark has recorded a strong annual growth in recent years, with its economy expanding 3.7 % last year, Rewarded in a large part of pharmaceutical exports.
The NOVO Nordisk giant makes the famous weight management drugs OzemPic and Wegov.
The Ministry of Economy noted that Denmark exports in the United States decreased dramatically in early 2025 after a significant rise in late 2024, due to the accumulation of stock and increased competition in the weight loss drugs market, which witnessed the loss of Novo in the market.
She said that the generic drugs are also pressing sales opportunities in the United States.
It has shook the drug sector in Europe this year before A threat to the higher American definitions in the skyAlthough some certainty has now been provided before European Union.
The Danish Ministry of Economy said that the American definitions were also weighing its growth expectations.
“The growth in the first quarter of 2025 was weaker than expected,” he said in a statement.
However, the ministry confirmed that despite the low growth expectations, its economy is still strong in general, as it is expected that the height of employment and inflation is less than 2 % on an annual basis.
This is an urgent news story and will be updated soon.
https://image.cnbcfm.com/api/v1/image/108192264-1756449058853-gettyimages-2197227349-AFP_36X97EX.jpeg?v=1756449071&w=1920&h=1080
Source link